Menu
Search
|

Menu

Close
X

GlycoMimetics Inc GLYC.OQ (NASDAQ Stock Exchange Global Market)

13.32 USD
+0.35 (+2.70%)
As of 4:00 PM EDT
Previous Close 12.97
Open 12.95
Volume 83,267
3m Avg Volume 105,867
Today’s High 13.38
Today’s Low 12.80
52 Week High 19.20
52 Week Low 8.29
Shares Outstanding (mil) 43.17
Market Capitalization (mil) 559.90
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.67 Mean rating from 6 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
EPS (USD)
FY18
-0.860
FY17
-1.151
FY16
-1.505
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
58.10
Price to Sales (TTM)
vs sector
--
8.84
Price to Book (MRQ)
vs sector
2.57
4.60
Price to Cash Flow (TTM)
vs sector
--
40.07
Total Debt to Equity (MRQ)
vs sector
0.00
17.66
LT Debt to Equity (MRQ)
vs sector
0.00
13.97
Return on Investment (TTM)
vs sector
-26.60
12.12
Return on Equity (TTM)
vs sector
-26.71
13.24

EXECUTIVE LEADERSHIP

M. James Barrett
Independent Chairman of the Board, Since 2017
Salary: --
Bonus: --
Rachel King
President, Chief Executive Officer, Co-Founder, Director, Since 2003
Salary: $502,500.00
Bonus: $301,500.00
John Magnani
Co-Founder, Senior Vice President, Chief Scientific Officer, Director, Since 2017
Salary: $378,000.00
Bonus: $181,440.00
Brian Hahn
Chief Financial Officer, Since 2012
Salary: $349,200.00
Bonus: $167,616.00
Helen Thackray
Senior Vice President - Clinical Development, Chief Medical Officer, Since 2017
Salary: $412,300.00
Bonus: $197,904.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

9708 Medical Center Dr
ROCKVILLE   MD   20850-3343

Phone: +1240.2431201

GlycoMimetics, Inc. is a clinical-stage biotechnology company. The Company focuses on the discovery and development of glycomimetic drugs. The Company operates through the identification and development of glycomimetic compounds segment. The Company is developing its lead drug candidate, GMI-1070 (Rivipansel), for the treatment of vaso-occlusive crisis (VOC), a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease. The Company is developing GMI-1271, a specific E-selectin inhibitor, to be used in combination with chemotherapy to treat patients with acute myeloid leukemia (AML), multiple myeloma (MM) and other hematologic cancers. The Company has an additional drug candidate, GMI-1359, that targets both E-selectin and a chemokine receptor, CXCR4. The Company is also advancing other preclinical-stage programs, which include small-molecule glycomimetic compounds that inhibit the proteins galectin-3 and galectin-9.

SPONSORED STORIES